Revision Skincare’s CMT Post‑Procedure Cream Wins 2026 NewBeauty Award — What Clinicians and Patients Need to Know

Table of Contents

  1. Key Highlights
  2. Introduction
  3. What CMT Post‑Procedure Cream Is — and Why It Matters
  4. The science behind the “neurocosmetic” label
  5. Clinical evidence and study design: what the data shows
  6. Ingredient breakdown: how the components support recovery
  7. How clinicians can integrate CMT into post‑procedure protocols
  8. Patient experience: what to expect during recovery
  9. Comparing CMT to other post‑procedure approaches
  10. What the NewBeauty Award signals about clinical practice trends
  11. Revision Skincare’s position: D•E•J focus and patient‑centric formulations
  12. Practical considerations for purchasing and clinic logistics
  13. Safety, contraindications, and special use cases
  14. Market context: why aftercare products are gaining center stage
  15. Illustrative case profiles (anonymized and representative)
  16. What clinicians should tell patients
  17. Industry reaction and next steps for research
  18. About NewBeauty and what the award means
  19. About Revision Skincare
  20. Final considerations for practices evaluating CMT
  21. FAQ

Key Highlights

  • Revision Skincare’s CMT Post‑Procedure Cream secured a 2026 NewBeauty Award in the In‑Office / Post‑Procedure category for its patent‑pending neurocosmetic technology and clinically demonstrated ability to relieve post‑procedure discomfort and reduce downtime.
  • Designed for compromised or stressed skin, the formula combines ceramides, sodium hyaluronate, pre‑ and postbiotics, antioxidants and botanical extracts at a skin‑neutral pH to support epidermal barrier regeneration and rebalance the skin’s microbiome when used after chemical peels, microneedling, and laser procedures.

Introduction

Post‑procedure care can determine whether a patient’s recovery is merely bearable or genuinely comfortable — and whether visible results achieve their full potential. Revision Skincare’s recent recognition by NewBeauty for its CMT Post‑Procedure Cream places the product at the center of a growing emphasis on post‑treatment recovery that protects the skin’s biology rather than simply masking symptoms.

The NewBeauty Awards have a long history of spotlighting clinically validated, practitioner‑trusted innovations in aesthetic care. This year’s nod highlights two trends converging in modern dermatologic practice: the rise of neurocosmetic interventions aimed at minimizing procedure‑related discomfort, and a renewed focus on the skin barrier and microbiome as essential elements in healing. The award follows clinical testing showing measurable relief within minutes of application and a protocol of up to three applications per day for seven days after professional treatments.

This article explains what CMT Post‑Procedure Cream is, why its approach matters to clinicians and patients, the science and clinical evidence behind its claims, how it fits into post‑procedure workflows, and what the recognition means for the broader field of aesthetic medicine.

What CMT Post‑Procedure Cream Is — and Why It Matters

Revision Skincare positions CMT Post‑Procedure Cream as the first neurocosmetic post‑procedure product clinically proven to decrease discomfort and reduce downtime after in‑office procedures. NewBeauty describes it as “a staple in many treatment rooms,” a shorthand for a product that aesthetic providers keep on hand because it reliably addresses immediate post‑treatment needs.

The cream is explicitly formulated for compromised or stressed skin following interventions such as chemical peels, microneedling, and laser treatments. Its intended functions are threefold:

  • Calm acute post‑procedure sensations and discomfort;
  • Support epidermal barrier regeneration; and
  • Replenish and rebalance the skin’s native microbiome.

These objectives reflect a shift away from treating post‑procedure redness and stinging as purely cosmetic problems. Instead, the product is designed to support physiological repair processes that lead to better outcomes and faster, more comfortable recoveries.

The science behind the “neurocosmetic” label

Neurocosmetics refers to topical strategies that target the cutaneous nervous system and neurogenic inflammation — the processes by which sensory neurons and neuropeptides influence redness, burning, itching, and pain in the skin. Rather than acting solely as an occlusive or broad anti‑inflammatory, neurocosmetic approaches aim to modulate the sensory signals that amplify discomfort after procedures that disrupt the epidermis.

Revision calls the technology behind CMT “patent‑pending neurocosmetic” technology. The company’s clinical claims — including rapid relief within 20 minutes — are consistent with an approach that addresses neural signaling in addition to barrier repair. Neurocosmetic mechanisms commonly used in the industry include peptides or botanical actives that reduce release of pro‑inflammatory neuropeptides, ingredients that normalize sensory receptor activity, and compounds that calm local neurogenic inflammation without systemic immunosuppression.

Key distinctions between a neurocosmetic strategy and other post‑procedure options:

  • Occlusives (petrolatum, ointments): create a protective film to prevent transepidermal water loss and protect against pathogens; they do not actively modulate neural signaling.
  • Topical corticosteroids: suppress immune activity and inflammation but can thin skin with prolonged use and are not recommended for routine post‑procedure care in many aesthetic contexts.
  • Neurocosmetics: complement barrier support and hydration with targeted modulation of sensory pathways to reduce burning, stinging, and perceived discomfort rapidly and without systemic effects.

This blended approach — calming sensory pathways while rebuilding barrier structure and supporting microbiome health — is attractive for in‑office protocols where patient comfort and quick recovery are priorities.

Clinical evidence and study design: what the data shows

Revision reports that CMT Post‑Procedure Cream is clinically proven to decrease discomfort and reduce downtime after in‑office procedures. The clinical program described in the company materials highlights several practical features:

  • Study population: patients who had undergone professional aesthetic procedures (examples listed: chemical peels, microneedling, laser).
  • Application regimen: applied after professional treatment and used up to three times daily for seven days.
  • Outcomes reported: rapid relief of discomfort, with demonstrated relief within 20 minutes of application; support for epidermal barrier regeneration and reduced downtime across the recovery period.

The methods described — immediate post‑procedure application followed by repeated use over seven days — mirror typical clinician instructions for post‑treatment topical care. The observation of relief within 20 minutes suggests a mechanism that includes sensory modulation rather than only slower barrier repair processes.

Reading clinical claims requires attention to study endpoints and controls. The available wording highlights reduction in patient‑reported discomfort and decreased downtime, endpoints that are especially relevant in aesthetic practice where subjective experience and return‑to‑social timelines matter. Reduction in “downtime” may reflect fewer visible signs (redness, swelling), improved comfort leading patients to resume normal activities sooner, or both.

For clinicians, the practical implication is that CMT may offer measurable improvements in the immediate, early, and mid‑term recovery windows — the periods when most patients seek reassurance and symptom relief.

Ingredient breakdown: how the components support recovery

CMT Post‑Procedure Cream combines several ingredient classes chosen to address hydration, barrier repair, microbiome balance, antioxidant protection, and sensory modulation. The product’s pH is described as skin‑neutral, an important attribute when applying to compromised skin.

Key components cited and their functional roles:

  • Ceramides
    • Function: Essential lipids of the stratum corneum that maintain barrier integrity and reduce transepidermal water loss.
    • Relevance: Ceramide replenishment aids reconstitution of the epidermal lipid matrix disrupted by ablative and non‑ablative procedures, supporting structural repair and reducing sensitivity.
  • Sodium hyaluronate
    • Function: The salt form of hyaluronic acid; smaller molecules of sodium hyaluronate penetrate more readily to provide water‑binding and plumping effects.
    • Relevance: Immediate enhancement of hydration reduces tightness and can attenuate visible flaking, supporting patient comfort and perceived recovery.
  • Pre‑ and postbiotics
    • Function: Prebiotics feed beneficial skin microbes; postbiotics are metabolites or cellular components derived from microbes that can have anti‑inflammatory or barrier‑supporting effects.
    • Relevance: Professional procedures can disturb the skin microbiome. Ingredients that help rebalance microbial communities and deliver microbial metabolites may reduce colonization risk by opportunistic organisms and support barrier repair pathways.
  • Antioxidants
    • Function: Scavenge free radicals and reduce oxidative stress produced during and after some energy‑based procedures.
    • Relevance: Antioxidants can minimize secondary cellular damage and inflammation that extend recovery.
  • Botanical extracts
    • Function: A broad category including anti‑inflammatory, calming, and antioxidant botanical actives.
    • Relevance: Botanical compounds often provide soothing and anti‑irritant benefits that complement the other functional ingredients.

Together, these ingredients create a multi‑pronged strategy: immediate hydration and soothing, structural lipid replacement to rebuild the barrier, and microbiome support to normalize the skin ecosystem. Coupled with the neurocosmetic element, the formulation addresses both the symptom (pain, burning, stinging) and the biological drivers of prolonged recovery.

How clinicians can integrate CMT into post‑procedure protocols

A primary reason clinics adopt a post‑procedure product is to standardize patient care and set expectations. Revision designed CMT for professional use, and its clinical program reflects common in‑office workflows. Practical integration points:

  • Immediate application in the treatment room
    • Rationale: Applying the cream immediately after a procedure delivers rapid relief at the moment symptoms tend to peak and begins barrier support without delay. The company’s data showing relief within 20 minutes supports immediate application.
  • Short‑term home application (up to three times daily for seven days)
    • Rationale: Continuing topical support through the critical first week sustains hydration, barrier rebuilding, and microbiome balance when the skin is most vulnerable. Three daily applications match patients’ schedules and ensures persistent benefits between visits.
  • Compatibility with different procedures
    • Use following superficial to medium chemical peels, microneedling, and many laser procedures (both ablative and nonablative) as directed by the treating clinician.
    • Clinicians should assess case by case for deeper ablation or when specialist wound care protocols are required.
  • Protocol notes for clinicians
    • Avoid combining with other actives (retinoids, aggressive exfoliants, strong acids) during the initial recovery period.
    • If using adjunctive agents (topical antibiotics, sitter ointments for specific case types), evaluate interactions and prioritize treatments based on the patient’s infection risk and healing trajectory.
    • Document baseline skin condition and provide patients with written guidance on application frequency, signs of complications, and when to seek follow‑up.

The product’s professional positioning means clinics can offer it at the point of care and incorporate it into aftercare kits. For patients, that single familiar regimen reduces confusion and encourages adherence, which correlates with better outcomes.

Patient experience: what to expect during recovery

Patient expectations shape satisfaction more than technical outcomes. The combination of rapid sensory relief and barrier‑supporting ingredients aims to shorten the window during which patients feel uncomfortable or self‑conscious.

A typical recovery timeline when CMT is used according to clinical directions:

  • Immediate (0–1 hour post‑procedure): Patients often report less intense burning or stinging compared with untreated controls, reflecting the neurocosmetic effect that modulates sensory signaling.
  • Early recovery (first 24–72 hours): Hydration from sodium hyaluronate and occlusive/semio‑occlusive effects reduce tightness and visible flaking starts to diminish; ceramide content supports barrier structure.
  • Days 3–7: Microbiome‑supporting ingredients help reestablish a balanced surface ecosystem; reduced redness and scaling produce earlier objective improvement and faster social‑readiness for many patients.
  • After one week: When used consistently, the skin often shows more resilient appearance and improved comfort compared with standard post‑procedure care alone.

Real‑world examples clinicians report in similar contexts include:

  • A patient undergoing microneedling who returns to routine activities sooner because stinging and redness resolve faster.
  • A chemical peel patient who avoids prolonged crusting and experiences less downtime, allowing an earlier return to work or events.

Clinicians should counsel patients that individual responses vary and that deeper resurfacing procedures may require tailored wound care. The product is intended to support typical in‑office aesthetic protocols rather than to replace specialized wound management.

Comparing CMT to other post‑procedure approaches

Post‑procedure care options range from simple emollients to sophisticated formulations and prescription medications. Understanding where CMT fits helps clinicians choose the best approach for each patient.

  • Emollients and occlusives
    • Strengths: Affordable, protective barrier; excellent at preventing water loss.
    • Limitations: Do not actively modulate sensation or microbiome; may feel greasy and are sometimes less acceptable for visible areas.
  • Antiseptic or antibiotic topicals
    • Strengths: Reduce infection risk in high‑risk wounds.
    • Limitations: Not necessary for routine superficial procedures; overuse can disrupt the microbiome.
  • Low‑potency topical corticosteroids
    • Strengths: Potent anti‑inflammatory effects.
    • Limitations: Risk of skin thinning and delayed barrier restoration with repetitive or prolonged use; generally avoided for everyday post‑procedure maintenance.
  • Medical‑grade recovery creams with multi‑ingredient profiles (e.g., CMT)
    • Strengths: Designed to target multiple aspects of recovery—sensory modulation, hydration, barrier repair, microbiome support—without systemic effects.
    • Limitations: Higher cost than basic emollients; professional preference and patient history guide selection.

The advantage of a product such as CMT lies in the combination of rapid symptom relief and supportive ingredients that align with physiologic recovery rather than bluntly suppressing inflammatory responses. For many practices, this combination translates to higher patient satisfaction and fewer post‑procedure calls or visits.

What the NewBeauty Award signals about clinical practice trends

Industry awards are not definitive proof of efficacy, but they reflect peer recognition, editorial vetting, and market acceptance. NewBeauty’s In‑Office / Post‑Procedure category highlights products practitioners actually use, not only consumer favorites. CMT’s recognition signals several trends:

  • Clinician demand for evidence‑backed, multi‑functional aftercare products that address both comfort and barrier restoration.
  • Rising interest in neurocosmetic approaches that reduce patient discomfort rapidly without systemic or steroidal therapies.
  • Increased value placed on microbiome‑friendly formulas as clinicians become more aware of the role of microbial communities in healing and long‑term skin health.

For aesthetic practices, adoption of such products becomes part of broader efforts to optimize patient experience, reduce complications, and differentiate services in a crowded marketplace.

Revision Skincare’s position: D•E•J focus and patient‑centric formulations

Revision Skincare frames its mission around the Dermal‑Epidermal Junction (D•E•J), which it calls the “Longevity Layer™.” The D•E•J is a structural and signaling interface between the epidermis and dermis; its integrity influences epidermal renewal and overall skin resilience. Revision has emphasized physician‑validated, medical‑grade formulations for over two decades and claims to design products that respect — rather than disrupt — the microbiome.

CMT aligns with that philosophy: rather than overriding the skin’s biology with aggressive anti‑inflammatory agents, it supports native repair mechanisms and microbial balance while providing sensory relief. This approach appeals to clinicians focused on long‑term skin health as well as immediate outcomes.

Practical considerations for purchasing and clinic logistics

Clinicians evaluating post‑procedure products must balance efficacy, safety, supply logistics, and patient cost. Relevant considerations for CMT:

  • Point‑of‑care stocking: Having the product available for immediate in‑clinic application reduces variability in aftercare and reinforces clinician recommendations.
  • Retailing to patients: Offering product in branded aftercare kits supports adherence and provides revenue to the practice; training front‑desk staff in brief counseling points (how often to apply, when to call) improves patient use.
  • Education: Clinician and staff education on neurocosmetic principles and ingredient actions allows confident recommendations and anticipatory guidance for patients receiving varied procedures.
  • Cost and insurance: Post‑procedure topical care is typically an out‑of‑pocket expense; practices can present it as an investment in comfort and potentially shorter downtime.

Clinics that integrate evidence‑backed post‑procedure products into standardized protocols often report fewer post‑op calls and higher satisfaction scores, benefits that justify modest retail markups.

Safety, contraindications, and special use cases

CMT was formulated for use on compromised or stressed skin following aesthetics procedures. Safety considerations include:

  • Applicability: Appropriate for many chemical, mechanical, and thermal energy‑based procedures when used as directed by a healthcare professional.
  • Allergies and sensitivities: As with any topical, clinicians should review ingredient lists for patient allergies. Patch testing for patients with a history of contact dermatitis is prudent.
  • Deep wounds and complex wounds: Deeper surgical wounds, full‑thickness tissue loss, or cases with high infection risk require specialist wound care; a multi‑disciplinary decision should guide topical selection.
  • Pediatric or pregnant patients: Clinicians should evaluate the safety profile of botanicals and other actives on a case‑by‑case basis.

The professional framing of the product reinforces the need for clinician oversight rather than unsupervised use after intensive procedures.

Market context: why aftercare products are gaining center stage

The aesthetic industry has moved beyond procedural excellence alone. Outcomes now depend on a continuum that includes pre‑treatment optimization, procedural skill, and careful post‑procedure care. Several market pressures elevate aftercare products:

  • Patient expectations: Faster return to normal life and minimal visible downtime are frequently requested outcomes.
  • Competitor differentiation: Practices that minimize downtime and discomfort can position themselves more favorably in consumer decision making.
  • Evidence‑focused purchasing: Clinics increasingly prefer products with clinical data that tie directly to patient‑reported outcomes.
  • Microbiome awareness: As research highlights the microbiome’s role in inflammation and repair, formulations that safeguard microbial balance gain traction.

Revision winning a NewBeauty award for a post‑procedure cream reflects these market dynamics and suggests practitioners value products offering demonstrable, rapid benefits that respect skin biology.

Illustrative case profiles (anonymized and representative)

The following are illustrative scenarios constructed to show how the product might be used in typical practices. These are intended as educational examples and not as endorsements of specific outcomes.

Case A — Microneedling for acne scars

  • Patient profile: 34‑year‑old with rolling acne scarring and Fitzpatrick III skin type seeking skin texture improvement.
  • Protocol: Fractional microneedling session performed with topical numbing.
  • CMT use: Applied immediately post‑procedure in clinic; patient instructed to apply up to three times daily for seven days.
  • Outcome: Patient reported reduced stinging within minutes after the initial application, experienced less flaking on days 3–5, and returned to work on day 4 with minimal visible irritation.

Case B — Non‑ablative fractional laser for pigmentation

  • Patient profile: 46‑year‑old seeking improvement in solar lentigines and overall tone.
  • Protocol: Non‑ablative fractional laser followed by cooling and topical application.
  • CMT use: Clinic applied the cream before leaving and provided a tube in the aftercare kit with instructions for twice daily use (within the allowed three times daily).
  • Outcome: Patient reported decreased redness and burning compared with prior noncuing experiences and resumed social activities sooner with greater satisfaction.

Case C — Superficial chemical peel for photoaging

  • Patient profile: 55‑year‑old with photodamage and fine lines.
  • Protocol: Superficial TCA or medium‑depth glycolic peel depending on provider; post‑peel care included recommended products.
  • CMT use: Applied after neutralization and repeated over seven days.
  • Outcome: Improved patient comfort and fewer post‑peel calls for concerns; provider noted less excessive desquamation in some patients.

These vignettes illustrate common use patterns. Outcomes depend on individual patient biology, procedure depth, and adherence.

What clinicians should tell patients

Clear, concise aftercare instructions reduce anxiety and improve compliance. Suggested talking points when offering CMT as part of post‑procedure care:

  • “We’ll apply a cream right after your treatment that helps soothe and hydrate your skin.” (Avoid technical jargon if the patient prefers.)
  • “Use this product as directed — up to three times a day for the first week — unless you are told otherwise.”
  • “Avoid other active ingredients and direct sun exposure during healing; use a broad‑spectrum sunscreen once cleared.”
  • “Call the clinic if you notice increasing pain, signs of infection (increasing warmth, pustules), or if you have any concerns.”

Providing a printed or digital aftercare sheet reinforces verbal instructions and reduces follow‑up burden on staff.

Industry reaction and next steps for research

Recognition by NewBeauty raises visibility and invites further clinical validation. Areas where additional data would strengthen the product’s position include:

  • Randomized controlled comparisons against standard emollients or other marketed post‑procedure formulas to quantify differences in measurable endpoints (erythema scores, time to social‑readiness).
  • Objective biomarkers of barrier recovery (e.g., transepidermal water loss, TEWL) and microbiome sequencing to demonstrate compositional shifts.
  • Larger, procedure‑specific cohorts to delineate efficacy across depths of resurfacing and laser modalities.

Clinicians seeking to adopt new post‑procedure products should weigh existing clinical evidence, their patient population, and operational considerations. For Revision, the NewBeauty award validates the product’s acceptance among editors and practitioners and may accelerate broader use.

About NewBeauty and what the award means

NewBeauty, a division of MJH Life Sciences, has established itself as an editorial authority on beauty and aesthetics since its founding in 2005. The NewBeauty Awards select noteworthy products with input from editors and industry experts; winners represent items that editorial teams judge to be notable for innovation, efficacy, or clinical utility. The In‑Office / Post‑Procedure category focuses specifically on products integrated within professional practices.

Earning a NewBeauty Award does not replace regulatory or clinical scrutiny, but it signals peer recognition and consumer awareness, which often translates into increased practitioner consideration and patient inquiries.

About Revision Skincare

Revision Skincare has marketed medical‑grade formulations for more than 20 years, emphasizing patent‑protected innovations and a philosophy that targets skin longevity through the Dermal‑Epidermal Junction (D•E•J) — its proprietary “Longevity Layer™.” The company highlights physician‑validated clinical testing and a goal of supporting long‑term skin health without disrupting the microbiome. CMT Post‑Procedure Cream sits within that lineage, combining a targeted neurocosmetic approach with barrier and microbiome‑focused ingredients.

Final considerations for practices evaluating CMT

Adopting a new post‑procedure cream should follow a straightforward process:

  • Review clinical data and label claims to ensure alignment with your patient population.
  • Trial the product in a range of routine procedures and document outcomes, both objective and patient‑reported.
  • Train clinical staff on application timing, patient counseling, and contraindications.
  • Incorporate the product into standardized aftercare kits to reduce variability and increase adherence.

For many practices, products that combine rapid symptom relief with barrier and microbiome support are a practical investment in patient experience and may reduce post‑treatment complications and calls.

FAQ

Q: What types of procedures is CMT Post‑Procedure Cream appropriate for? A: The cream is formulated for use after chemical peels, microneedling, and various laser procedures. It is intended for compromised or stressed skin when used as directed by a healthcare professional. For deeper surgical wounds or complex cases, follow specialized wound care protocols.

Q: How quickly does the cream reduce discomfort? A: Revision reports clinically demonstrated relief within 20 minutes of application in their studies. The product’s neurocosmetic components are designed to target sensory discomfort rapidly while other ingredients support barrier repair over days.

Q: How often should a patient apply the cream? A: Clinical studies used applications up to three times daily for seven days following the professional treatment. Clinicians should provide personalized instructions based on the specific procedure and patient factors.

Q: Can CMT be used in combination with other topical products? A: Combining topicals requires clinical judgment. During the immediate recovery period, it’s prudent to avoid potent actives (strong retinoids, exfoliating acids) and to prioritize products that support healing. If adjunctive agents are necessary for infection control or other specific indications, clinicians should evaluate compatibility.

Q: Is the cream safe for sensitive or allergy‑prone skin? A: The formula is intended for compromised or stressed skin and is skin‑neutral in pH. Patients with a history of contact dermatitis or known allergies should have ingredients reviewed and, if warranted, perform a patch test under clinical supervision.

Q: Does CMT replace the need for prescription medications after a procedure? A: No. CMT is designed as a post‑procedure support product to improve comfort and support recovery in routine aesthetic procedures. Prescription medications — such as antibiotics or specialized wound care agents — remain necessary when indicated by the procedure type or patient risk factors.

Q: Will CMT prevent infection after procedures? A: The cream supports barrier repair and microbiome balance, which can reduce vulnerability during healing. It is not an antiseptic or a substitute for targeted antimicrobial therapy when infection risk is present. Clinicians should follow established infection‑prevention protocols.

Q: What does “neurocosmetic” mean in this context? A: The term refers to topical strategies that modulate the skin’s sensory pathways and neurogenic inflammation to reduce sensations such as burning, stinging, or itching. Revision’s patent‑pending technology aims to deliver rapid symptomatic relief while preserving healing processes.

Q: How should clinics stock and retail the product? A: Many practices keep a supply for in‑clinic immediate application and include the product in take‑home aftercare kits. Training front‑desk and clinical staff on counseling points and clear usage instructions improves adherence and patient outcomes.

Q: Why does the NewBeauty Award matter? A: The award indicates editorial and industry recognition. NewBeauty’s In‑Office / Post‑Procedure category focuses on products used by professionals. While awards are not a substitute for rigorous clinical evaluation, they reflect peer and editorial endorsement that can influence practitioner adoption.

Q: Where can clinicians and patients find more information? A: Full product details, clinical information, and purchasing options are available through Revision Skincare’s official channels and professional representatives. Clinicians are encouraged to review the product’s technical materials and clinical data before integrating it into practice.

Q: Are there plans for further studies or broader indications? A: Revision has positioned the product with clinical data supporting its primary use. Future research directions that would strengthen adoption include randomized controlled trials versus standard care and larger, procedure‑specific cohorts; clinicians interested in clinical partnerships should consult Revision’s professional relations team.

The shift toward evidence‑based, biology‑respecting post‑procedure care is changing how clinics manage recovery. Revision Skincare’s CMT Post‑Procedure Cream exemplifies a multi‑modal approach that aims to reduce patient discomfort quickly while actively supporting barrier restoration and microbiome balance. Its recognition by NewBeauty reflects practitioner uptake and editorial endorsement; clinicians evaluating post‑treatment protocols should weigh this product alongside other options to determine which best aligns with patient needs and practice workflows.